Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases
- PMID: 9302266
- DOI: 10.1093/hmg/6.11.1879
Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases
Abstract
Tay-Sachs and Sandhoff diseases are autosomal recessive neurodegenerative diseases resulting from the inability to catabolize GM2 ganglioside by beta-hexosaminidase A (Hex A) due to mutations of the alpha subunit (Tay-Sachs disease) or beta subunit (Sandhoff disease) of Hex A. Hex B (beta beta homodimer) is also defective in Sandhoff disease. We previously developed mouse models of both diseases and showed that Hexa-/- (Tay-Sachs) mice remain asymptomatic to at least 1 year of age while Hexb-/- (Sandhoff) mice succumb to a profound neurodegenerative disease by 4-6 months of age. Here we find that neuron death in Hexb-/- mice is associated with apoptosis occurring throughout the CNS, while Hexa-/- mice were minimally involved at the same age. Studies of autopsy samples of brain and spinal cord from human Tay-Sachs and Sandhoff diseases revealed apoptosis in both instances, in keeping with the severe expression of both diseases. We suggest that neuron death is caused by unscheduled apoptosis, implicating accumulated GM2 ganglioside or a derivative in triggering of the apoptotic cascade.
Similar articles
-
Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.Hum Mol Genet. 1996 Jan;5(1):1-14. doi: 10.1093/hmg/5.1.1. Hum Mol Genet. 1996. PMID: 8789434
-
Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.Nat Genet. 1995 Oct;11(2):170-6. doi: 10.1038/ng1095-170. Nat Genet. 1995. PMID: 7550345
-
[Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].Yakugaku Zasshi. 2013;133(2):269-74. doi: 10.1248/yakushi.12-00199. Yakugaku Zasshi. 2013. PMID: 23370522 Review. Japanese.
-
The biochemistry of HEXA and HEXB gene mutations causing GM2 gangliosidosis.Biochim Biophys Acta. 1991 Feb 22;1096(2):87-94. doi: 10.1016/0925-4439(91)90044-a. Biochim Biophys Acta. 1991. PMID: 1825792 Review. No abstract available.
-
[Recent advances in molecular genetics of GM2 gangliosidosis].Nihon Rinsho. 1995 Dec;53(12):2988-93. Nihon Rinsho. 1995. PMID: 8577047 Review. Japanese.
Cited by
-
Characterization of a phenotypically severe animal model for human AB-Variant GM2 gangliosidosis.Front Mol Neurosci. 2023 Nov 30;16:1242814. doi: 10.3389/fnmol.2023.1242814. eCollection 2023. Front Mol Neurosci. 2023. PMID: 38098938 Free PMC article.
-
An in vitro approach to understand contribution of kidney cells to human urinary extracellular vesicles.J Extracell Vesicles. 2023 Feb;12(2):e12304. doi: 10.1002/jev2.12304. J Extracell Vesicles. 2023. PMID: 36785873 Free PMC article.
-
Infantile Sandhoff disease with ventricular septal defect: a case report.J Med Case Rep. 2022 Aug 25;16(1):317. doi: 10.1186/s13256-022-03550-0. J Med Case Rep. 2022. PMID: 36002893 Free PMC article.
-
Therapeutic advantages of combined gene/cell therapy strategies in a murine model of GM2 gangliosidosis.Mol Ther Methods Clin Dev. 2022 Mar 16;25:170-189. doi: 10.1016/j.omtm.2022.03.011. eCollection 2022 Jun 9. Mol Ther Methods Clin Dev. 2022. PMID: 35434178 Free PMC article.
-
The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.Neurosci Lett. 2021 Nov 1;764:136195. doi: 10.1016/j.neulet.2021.136195. Epub 2021 Aug 25. Neurosci Lett. 2021. PMID: 34450229 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous